Screener
Revvity RVTY Life Sciences — Depreciation
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Revvity in its filing.
Tagged under the XBRL concept us-gaap:Depreciation.
The source filing: Revvity’s 10-Q, filed May 12, 2026.
- Filed
- May 12, 2026, 4:07 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0000031791-26-000019
FAQ
- What is Revvity's life sciences — depreciation?
- Revvity (RVTY) reported life sciences — depreciation of $9.91M in Q1 2026.
- How has Revvity's life sciences — depreciation changed year-over-year?
- Revvity's life sciences — depreciation increased by 37.9% year-over-year, from $7.19M to $9.91M.
- What is the long-term trend for Revvity's life sciences — depreciation?
- Over 3 years (2022 to 2025), Revvity's life sciences — depreciation has grown at a 11.0% compound annual growth rate (CAGR), from $24.51M to $33.49M.
- What does life sciences — depreciation mean?
- The systematic allocation of the cost of tangible assets, such as machinery and laboratory equipment, over their useful lives within the Life Sciences segment. This reflects the wear and tear of capital assets used in production.
Ask your AI about Revvity's life sciences — depreciation.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude